Reuters Reported Pfizer/Biontech Agree To Amend COVID Vaccine Contract To Reduce Number EU Must Buy
Portfolio Pulse from Charles Gross
Pfizer and BioNTech have agreed to amend their COVID-19 vaccine contract with the European Union, reducing the number of vaccines the EU must purchase.
May 26, 2023 | 8:44 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
The amended Pfizer/BioNTech contract may have a limited impact on the European market ETF.
While the contract amendment may affect Pfizer and BioNTech's sales, its impact on the broader European market and the VGK ETF is likely to be limited, as the healthcare sector is just one component of the market.
CONFIDENCE 70
IMPORTANCE 30
RELEVANCE 20
NEGATIVE IMPACT
BioNTech's contract amendment with the EU may result in decreased vaccine sales.
As Pfizer's partner, BioNTech will also be affected by the contract amendment, potentially leading to lower sales and revenue for the company in the short term.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 50
NEGATIVE IMPACT
Pfizer's contract amendment with the EU may lead to reduced vaccine sales.
The contract amendment reduces the number of vaccines the EU must purchase from Pfizer, which could lead to lower sales and revenue for the company in the short term.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 50